Dexazone - instructions for use, dose, side effects, contraindications

The drug is used for diseases requiring the introduction of a fast-acting glucocorticosteroid, and also in those cases when oral administration of the drug is impossible:

- Endocrine diseases: acute insufficiency of the adrenal cortex, primary or secondary insufficiency of the adrenal cortex, congenital hyperplasia of the adrenal cortex, subacute thyroiditis;

- shock resistant to standard therapy; anaphylactic shock;

- edema of the brain (with a brain tumor, craniocerebral trauma, neurosurgical intervention, cerebral hemorrhage, encephalitis, meningitis, radiation injury);

- asthmatic status; severe bronchospasm (exacerbation of bronchial asthma, chronic obstructive bronchitis);

- severe allergic reactions;

- rheumatic diseases;

- systemic connective tissue diseases;

- Acute severe dermatoses;

- malignant diseases: palliative treatment of leukemia and lymphoma in adult patients; acute leukemia in children; hypercalcemia in patients with malignant tumors, with the impossibility of oral treatment;

- Diagnostic examination of adrenal hyperfunction;

- blood diseases: acute hemolytic anemia, agranulocytosis, idiopathic thrombocytopenic purpura in adults;

- severe infectious diseases (in combination with antibiotics);

- in ophthalmic practice (subconjunctival, retrobulbar or parabulbar injection): allergic conjunctivitis, keratitis, keratoconjunctivitis without epithelial damage, irit, iridocyclitis, blepharitis, blepharoconjunctivitis, scleritis, episcleritis, inflammatory process after eye injuries and surgical interventions, sympathetic ophthalmia, immunosuppressive treatment after corneal transplantation;

- intraarticular and intrasynovial administration: arthritis of various etiologies, osteoarthritis, acute and subacute bursitis, acute tendovaginitis, epicondylitis, synovitis;

- local application (in the area of pathological education): keloids, discoid lupus erythematosus, annular granuloma.

Contraindications:

- Increased individual sensitivity to the drug;

- systemic fungal infections;

- severe osteoporosis:

- severe myopathies (with the exception of myasthenia gravis);

- viral infections, poliomyelitis (with the exception of the bulbar-encephalic form);

- lymphadenitis after vaccination with BCG;

- idiopathic thrombocytopenic purpura (with intramuscular injection of the drug);

- infectious lesions of joints and periarticular tissues.

Carefully:Dexazone should be used with extreme caution: with nonspecific ulcerative colitis, if there is a threat of perforation; with the diverticulum of the intestine; with the newly created intestinal anastomosis; in case of peptic ulcer; with renal insufficiency; Acquired Immunodeficiency Syndrome (AIDS); arterial hypertension; diabetes mellitus; osteoporosis; myasthenia gravis; glaucoma; with mental illness in the anamnesis; in children.

Pregnancy and lactation:

During pregnancy (especially in the first trimester) the drug can be applied only when the expected therapeutic effect exceeds the potential risk to the fetus. With prolonged therapy during pregnancy, the possibility of impaired fetal growth is not ruled out. In case of application at the end of pregnancy, there is a risk of atrophy of the adrenal cortex in the fetus, which may require replacement therapy in the newborn.

If it is necessary to carry out treatment with the drug during breastfeeding, then breastfeeding should be discontinued.

Dosing and Administration:

The dosage regimen is individual and depends on the indications, the patient's condition and his reaction to therapy.

The drug is administered intravenously slowly by jet or drip (in acute and urgent conditions); intramuscularly; possibly also intraarticular, intrasynovial and local (in pathological education) introduction. During the day, you can inject 4 to 20 mg of Dexazone 3-4 times. The duration of parenteral use is usually 3-4 days, then switch to maintenance therapy with an oral form.

In an acute period with various diseases and at the beginning of therapy, Dexazone is used in higher doses.

When the effect is achieved, the dose is reduced until reaching a maintenance dose or until the treatment is terminated.

Side effects:

The risk of side effects increases with the duration of the course of treatment.

From the side of metabolism: delay sodium and water in the body; hypokalemia; hypokalemic alkalosis; negative nitrogen balance, caused by increased protein catabolism.

From the cardiovascular system: a higher risk of thrombus formation (especially in immobilized patients), arterial hypertension, congestive heart failure in patients with heart disease.

From the musculoskeletal system: muscle weakness, steroid myopathy, muscle mass reduction, osteoporosis, vertebral compression fractures, aseptic necrosis of the head of the femoral and humerus bones, pathological fractures of long bones.

From the digestive system: erosive and ulcerative lesions of the gastrointestinal tract (which can cause perforations and bleeding), pancreatitis, ulcerative esophagitis.

Dermatological reactions: thinning and vulnerability of the skin, petechiae and subcutaneous hemorrhages, ecchymosis, striae, steroid acne, delayed wound healing, increased sweating.

From the central nervous system: dizziness, headaches, mental disorders, seizures and false brain tumor symptoms (increased intracranial pressure with a congestive optic nerve disc).

From the endocrine system: disorders of the menstrual cycle, Cushing's syndrome, growth retardation in children, a decrease in glucose tolerance, hyperglycemia up to the development of steroid diabetes, an increase in insulin or oral hypoglycemic agents in patients with diabetes mellitus, adrenal insufficiency (especially during stress - with trauma, surgical operation, concomitant diseases).

From the side of the organ of vision: posterior subcapsular cataract, increased intraocular pressure, exophthalmos,

Side effects associated with immunosuppressive action:

More frequent occurrence of infections and aggravation of the severity of their course.

Other: allergic reactions.

Local reactions (at the site of administration): hyperpigmentation and leukoderma, atrophy of subcutaneous tissue and skin, aseptic abscess, hyperemia at the injection site, arthropathy.

Overdose:

It is possible to strengthen the described side effects. It is necessary to reduce the dose of Dexazone or to cancel the drug. Treatment is symptomatic.

Long-term use of high doses of the drug requires a gradual dose reduction in order to prevent the development of acute adrenocortical insufficiency.

Interaction:

Simultaneous use with phenobarbital, rifampicin, phenytoin or ephedrine can accelerate the biotransformation of dexazone, thereby weakening its effect.

Hormonal contraceptives enhance the action of Dexazone.

Simultaneous use with diuretics (especially "loop") can lead to increased excretion of potassium from the body.

With simultaneous use with cardiac glycosides, the possibility of cardiac arrhythmias increases.

Dexazone weakens (less intensifies) the effect of coumarin derivatives, which requires correction of their dose.

Dexazone enhances the side effects of non-steroidal anti-inflammatory drugs, especially their effect on the gastrointestinal tract (increased risk of erosive ulcerative lesions and bleeding from the gastrointestinal tract).In addition, it reduces the concentration of NSAIDs in the blood serum and, thereby, their effectiveness.

Special instructions:

The effect of the drug is enhanced in patients with hypothyroidism and liver cirrhosis.

Dexazone can mask the symptoms of infection.

The drug may enhance existing emotional instability or psychotic disorders.

In connection with the rare occurrence of anaphylactic reactions during parenteral therapy, all precautions should be taken before the administration of the drug (especially in patients with a tendency to drug allergy).

In stressful situations during maintenance treatment (for example, surgical operations, trauma or infectious diseases), a correction of the dose of the drug should be made in connection with an increase in the need for glucocorticosteroids.

It should be carefully monitored for patients within a year after the end of long-term therapy with glucocorticosteroids in connection with the possible development of a relative insufficiency of the adrenal cortex in stressful situations.

With long-term treatment should discuss the appropriateness of the transition from parenteral administration of the drug to ingestion.

During treatment with glucocorticosteroids, vaccination should not be given due to a decrease in its effectiveness and possible neurological complications. Dexazone is not prescribed for 8 weeks before and 2 weeks after vaccination.

Effect on the ability to drive transp. cf. and fur:

If side effects on the central nervous system occur (see the "Side effect" section), work with the mechanisms and management of vehicles should be discontinued.

Form release / dosage:Solution for injection, 4 mg / ml.

Packaging:

In ampoules of 1 ml.

Storage conditions:

At a temperature of no higher than 25 ° C, in a place protected from light.

Keep out of the reach of children.

Shelf life:

3 years.

Do not use after the expiry date indicated on thepacksheep.

Terms of leave from pharmacies:On prescription

Registration number:П N014411 / 02-2002

Date of registration:26.05.2010

Expiration Date:Unlimited

The owner of the registration certificate:Galenika ad.Galenika ad. Serbia and Montenegro

Manufacturer: & nbsp

GALENIKA, a.d. Serbia and Montenegro

Representation: & nbspGALENIKA A.D.GALENIKA A.D.Russia

Information update date: & nbsp20.03.2017

Illustrated instructions

Instructions

Dexazone (Dexason)